Biologics Financial

Isto and Arteriocyte join forces to form leading biologics player, Isto Biologics

isto-ams-merge

ST. LOUIS, Oct. 19, 2016 /PRNewswire/ — Isto Holdings, the parent company of St. Louis-based Isto Technologies – a leader in bone-regeneration technologies and cell-based therapy – has acquired medical-device company Arteriocyte Medical Systems Inc. ofHopkinton, Massachusetts, with plans to integrate the companies under the name Isto Biologics. Isto Biologics will be focused on offering evidence-based solutions to expand its spine, orthopedics, and functional-medicine product portfolios. Isto Biologics will be headquartered in St. Louis, while maintaining operations in Massachusetts.

“We’re excited to bring together two great organizations under the Isto umbrella and build upon their leading biologics platforms,” saidAnthony Chambers, Director at Thompson Street Capital Partners, which provided capital for the transaction. “Both Isto and Arteriocyte have achieved remarkable success by developing innovative, clinically-proven product offerings that help improve patient outcomes. The integrated product portfolio, combined with the expanded sales force and broader distribution network, will allow Isto Biologics to extend its reach within the spine, orthopedics, and functional-medicine markets.”

George Dunbar, current CEO of Isto Technologies, will serve as CEO of Isto Biologics. “We are grateful for the support of Thompson Street Capital Partners and excited to lead Isto Biologics into the future,” said Mr. Dunbar. “The integration of Isto and Arteriocyte presents an opportunity to leverage our combined expertise to establish a strong position in an ever-changing market and better serve our physician partners, as they work to grow their practice and meet the demands of value-based healthcare.”

Isto Biologics’ expanded, best-in-class product portfolio will feature Arteriocyte’s market-leading MAGELLAN® Autologous Platelet Separator and Isto’s bone-growth and cell-therapy products, including InQu® Bone Graft Extender & Substitute; Influx®, a natural bone-graft material; and CellPoint®, a concentrated bone marrow aspirate system.

About Isto Biologics

Isto Biologics was formed in 2016 when St. Louis-based Isto Technologies and Arteriocyte Medical Systems Inc. of Hopkinton, Massachusetts, integrated under the Isto Holdings umbrella. Isto Biologics is focused on offering evidence-based solutions for bone regeneration and cell therapy to help improve patient outcomes. The company’s best-in-class product offerings include Arteriocyte’s market-leading MAGELLAN® Autologous Platelet Separator and Isto’s bone-growth and cell-therapy products including InQu® Bone Graft Extender & Substitute; Influx®, a natural bone-graft material; and CellPoint®, a concentrated bone marrow aspirate system.

For more information, visit istobiologics.com.

Media Contact:
Jenny Reid
Director of Marketing
314-262-8039
JReid@istotech.com

Logo – http://photos.prnewswire.com/prnh/20161019/430449LOGO

 

SOURCE Isto Biologics

Related Links

http://www.istobiologics.com

About the author

Josh Sandberg

Josh Sandberg has been an executive search consultant focused exclusively on orthopedic and spine start-ups since 2004. He has had a tremendous impact in helping his clients avoid costly hiring mistakes by his deep industry knowledge and network. In 2010, Josh co-founded Ortho Spine Companies, which is the parent company of Ortho Spine Distributors (OSD), Surg.io and Ortho Sales Partners (OSP). OSD a searchable database that helps ease the frustration of finding orthopedic distributors throughout the country. Surg.io is the ultimate distributor toolkit that offers distributors the tools necessary to build the foundation of a scalable and highly functioning sales organization. OSP is an end-to-end solution that helps companies approach the Global Market in a cost efficient way. Our team has hundreds of years of experience and can help you navigate the many challenges present in bringing new technologies to the market.

Add Comment

Click here to post a comment

Your email address will not be published. Required fields are marked *

Download our App

OrthoSpineNews.com
Developer: Fifty Pixels Ltd
Price: Free
OrthoSpineNews
Developer: Fifty Pixels Ltd
Price: Free

Innovasis

Polls

With Conference Season Ending, Which Spine Conference Are You Looking Forward to the Most in 2017?

View Results

Loading ... Loading ...